EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma

Masanori Inoue iD, Sadahisa Ogasawara iD, Kazuhisa Asahara iD, Rui Sato iD, Shunji Watanabe, Haruka Anzai, Kazuo Tsubura, Taro Watabe, Makoto Fujiya, Teppei Akatsuka, Ryo Izai, Keiichi Katayama und 19 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71655 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Masanori Inoue und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Bevacizumab, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line regimens and evaluated post‐progression efficacy.

Methods

We retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort ( n = 612) excluded patients who underwent concomitant or inter‐line locoregional therapy or entered clinical trials after first‐line treatment. Overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan–Meier analysis and compared by the log‐rank test. The impact of disease control and objective response on OS was assessed using time‐dependent Cox models.

Results

Median OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev ( p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively ( p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively ( p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second‐line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev ( p = 0.001).

Conclusion

Atez/Bev provided superior survival and durable tumor control; however, post‐progression outcomes remained unsatisfactory, underscoring the need for improved second‐line approaches after Atez/Bev failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsBevacizumabCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedDisease ProgressionTreatment OutcomePhenylurea CompoundsSorafenibAdultQuinolinesProgression-Free Survival

Stichwörter der Autor:innen

atezolizumabbevacizumabduration of disease controlduration of responsehepatocellular carcinomasecond line

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabPhenylurea CompoundslenvatinibSorafenibQuinolines

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Masanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara, Rui Sato, Hiroaki Kanzaki, Keisuke Koroki, Masato Nakamura, Naoya Kanogawa, Michihisa Moriguchi, Takeshi Aramaki

Zitieren

APA

Inoue, M., Ogasawara, S., Asahara, K., Sato, R., Watanabe, S., Anzai, H., Tsubura, K., Watabe, T., Fujiya, M., Akatsuka, T., Izai, R., Katayama, K., Sawada, M., Tsuchiya, T., Miwa, C., Yoshino, R., Yonemoto, T., Fujimoto, K., Unozawa, H., …, & Morimoto, N. (2026). Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71655

Vancouver

Inoue M, Ogasawara S, Asahara K, Sato R, Watanabe S, Anzai H, et al. Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.71655

BibTeX
@article{Inoue2026,
  author = {Inoue, Masanori and Ogasawara, Sadahisa and Asahara, Kazuhisa and Sato, Rui and Watanabe, Shunji and Anzai, Haruka and Tsubura, Kazuo and Watabe, Taro and Fujiya, Makoto and Akatsuka, Teppei and Izai, Ryo and Katayama, Keiichi and Sawada, Midori and Tsuchiya, Takahiro and Miwa, Chihiro and Yoshino, Ryohei and Yonemoto, Takuya and Fujimoto, Kentaro and Unozawa, Hidemi and Yumita, Sae and Kanzaki, Hiroaki and Koroki, Keisuke and Kobayashi, Kazufumi and Nakamura, Masato and Kanogawa, Naoya and Nakamoto, Shingo and Yokoyama, Masayuki and Kato, Jun and Moriguchi, Michihisa and Aramaki, Takeshi and Morimoto, Naoki},
  title = {Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71655}
}
Kostenlos starten →